Head-to-head evidence
Daratumumab vs TJ202
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Myeloma
Shared mechanism: CD38 · full Multiple Myeloma pipeline
Daratumumab
Marketed by Johnson & Johnson
NCT02076009 · Phase 3 · completed
This was a large randomized, open-label trial with an active comparator, enrolling 286 participants in the daratumumab group and 283 in the control group. Progression-free survival was the hard clinical primary endpoint, but the registry does not report a complete treatment comparison or statistical significance for it, so the result cannot be clearly classified as met.
Next expected readout: October 2026 · NCT06140966 (registry estimate)
TJ202
Developed by TJ Biopharma Co., Ltd.
NCT03952091 · Phase 3 · completed
The study randomly assigned 289 participants to TJ202 plus lenalidomide and dexamethasone or to the active comparator regimen, but it was open-label rather than blinded. Its primary endpoint was the clinical measure of progression-free survival; because no results are posted, it is not possible to determine whether this endpoint was met.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Daratumumab's landscape · TJ202's landscape